Cationic Ru(η6-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones - Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents

Anticancer Ru and Os complexes of N-(4-chlorophenyl)pyridine-2-carbothioamide: Substitution of the labile chlorido ligand with phosphines

Half-sandwich M^II(cym)Cl (cym = η⁶-p-cymene; M = Ru, Os) complexes of pyridinecarbothioamide (PCA) ligands have demonstrated potential as orally active anticancer agents. In order to investigate the impact of the substitution of the labile chlorido ligand with phosphorous donor ligands on the antiproliferative properties, the triphenylphosphine (PPh₃) and 1,3,5-triaza-7-phophaadamantane (pta) analogues were prepared and characterized by spectroscopic techniques and the molecular structures of several complexes were determined by X-diffraction analysis. Interestingly, the molecular structures contained the PCA ligand deprotonated, presumably driven by the reduction in overall charge of the complex. Density Functional Theory (DFT) calculations suggested minor energy differences between the protonated and deprotonated forms. The aqueous stability and the reactivity with the amino acids l-histidine and l-cysteine were investigated by ¹H NMR spectroscopy of representative examples. The most potent anticancer agents featured Ru or Os centers and a PPh₃ ligand and showed IC₅₀ values in the submicromolar range against four cancer cell lines. This suggests that the antiproliferative activity was mainly dependent on the lipophilic properties of the phosphine ligand with PPh₃ having a significantly higher clog P value than pta.

Exploring pta Alternatives in the Development of Ruthenium-Arene Anticancer Compounds

Organoruthenium pyrithione (1-hydroxypyridine-2-thione) complexes have been shown in our recent studies to be a promising family of compounds for development of new anticancer drugs. The complex [(η⁶-p-cymene)Ru(pyrithionato)(pta)]PF₆ contains phosphine ligand pta (1,3,5-triaza-7-phosphaadamantane) as a functionality that improves the stability of the complex and its aqueous solubility. Here, we report our efforts to find pta alternatives and discover new structural elements to improve the biological properties of ruthenium anticancer drugs. The pta ligand was replaced by a selection of phosphine, phosphite, and arsine ligands to identify new functionalities, leading to improvement in inhibitory potency towards enzyme glutathione S-transferase. In addition, cytotoxicity in breast, bone, and colon cancers was investigated.

Ruthenium(II)-Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis

While ruthenium arene complexes have been widely investigated for their medicinal potential, studies on homologous compounds containing a tridentate tris(1-pyrazolyl)methane ligand are almost absent in the literature. Ruthenium(II) complex 1 was obtained by a modified reported procedure; then, the reactions with a series of organic molecules (L) in boiling alcohol afforded novel complexes 2–9 in 77–99% yields. Products 2–9 were fully structurally characterized. They are appreciably soluble in water, where they undergo partial chloride/water exchange. The antiproliferative activity was determined using a panel of human cancer cell lines and a noncancerous one, evidencing promising potency of 1, 7, and 8 and significant selectivity toward cancer cells. The tested compounds effectively accumulate in cancer cells, and mitochondria represent a significant target of biological action. Most notably, data provide convincing evidence that the mechanism of biological action is mediated by the inhibiting of mitochondrial calcium intake.

Role of the (pseudo)halido ligand in ruthenium(II) p-cymene α-amino acid complexes in speciation, protein reactivity and cytotoxicity

The reactions of the dimeric complexes [RuX2(η6-p-cymene)]2 (X = Br, I, SCN) with L-proline (ProH) and trans-4-hydroxy-L-proline (HypH), in methanol in the presence of NaOH, afforded [RuX(κ2N,O-Pro)(η6-p-cymene)] (X = Br, 1b; I, 1c; SCN, 1d) and [RuX(κ2N,O-Hyp)(η6-p-cymene)] (X = Br, 2b; I, 2c; SCN, 2d), respectively. Alternatively, the one-pot, sequential addition of the appropriate α-amino carboxylate and X- salt to [RuCl2(η6-p-cymene)]2 led to [RuX(κ2N,O-Pro)(η6-p-cymene)] (X = N3, 1e; NO2, 1f; CN 1g) and [Ru(N3)(κ2N,O-Hyp)(η6-p-cymene)] (2e). Complexes [Ru(κ3N,O,O'-O2CCH(NH2)(R)O)(η6-p-cymene)] (R = CH2, 3h; R = CHMe, 4h; R = CH2CH2, 5h) were prepared from the reaction of [RuCl2(η6-p-cymene)]2 with the appropriate α-amino acid and NaOH in refluxing isopropanol. Treatment of the L-serine (SerH2) derivative [RuCl(κ2N,O-SerH)(η6-p-cymene)] (3a) with 1,3,5-triaza-7-phosphaadamantane (PTA) in water at reflux produced [Ru(κ2N,O-Ser)(κP-PTA)(η6-p-cymene)]Cl ([3i]Cl). The products were isolated in good to excellent yields, and were characterized by elemental analysis, IR and multinuclear NMR spectroscopy. The structures of 1f and 2b-e were ascertained by X-ray diffraction studies. The behaviour of the complexes in water and cell culture medium was investigated by multinuclear NMR and UV-Vis spectroscopy, revealing a considerable influence of the monodentate ligand on the aqueous chemistry. Complexes 1d-e, 2d-e, 3h, 4h and [3i]Cl, showing substantial inertness in aqueous media, were assessed for their cytotoxicity towards A2780 and A2780cisR cancer cell lines and the noncancerous HEK 293T cell line. A selection of compounds was also investigated for Ru uptake in A2780 cells and interactions with cytochrome c as a model protein. Combined, these studies provide insights into the previously debated role of the 'leaving' ligand on the biological activity of Ru(II) arene α-amino acid complexes.

Anticancer Activity of Half-Sandwich Ru, Rh and Ir Complexes with Chrysin Derived Ligands: Strong Effect of the Side Chain in the Ligand and Influence of the Metal

An important challenge in the field of anticancer chemotherapy is the search for new species to overcome the resistance of standard drugs. An interesting approach is to link bioactive ligands to metal fragments. In this work, we have synthesized a set of p-cymene-Ru or cyclopentadienyl-M (M = Rh, Ir) complexes with four chrysin-derived pro-ligands with different -OR substituents at position 7 of ring A. The introduction of a piperidine ring on chrysin led to the highly cytotoxic pro-ligand HL4 and its metal complexes L4-M (SW480 and A549 cell lines, cytotoxic order: L4-Ir > L4-Ru ≈ L4-Rh). HL4 and its complexes induce apoptosis and can overcome cis-platinum resistance. However, HL4 turns out to be more cytotoxic in healthy than in tumor cells in contrast to its metal complexes which displayed higher selectivity than cisplatin towards cancer cells. All L4-M complexes interact with double stranded DNA. Nonetheless, the influence of the metal is clear because only complex L4-Ir causes DNA cleavage, through the generation of highly reactive oxygen species (1O2). This result supports the hypothesis of a potential dual mechanism consisting of two different chemical pathways: DNA binding and ROS generation. This behavior provides this complex with a great effectivity in terms of cytotoxicity.

Health beneficial and pharmacological properties of p-cymene

p-cymene also known as p-cymol or p-isopropyltoluene is an alkyl-substituted aromatic compound naturally occurring in essential oils (EOs) of various aromatic plants, including the genus of Artemisia, Protium, Origanum, and Thymus. It is related to the family of terpenes, especially monocyclic monoterpenes. p-cymene is also present in several food-based plants such as carrots, orange juice, grapefruit, tangerine, raspberries and several spices. Numerous studies have demonstrated the pharmacological properties of the monoterpenes p-cymene, including antioxidant, anti-inflammatory, antiparasitic, antidiabetic, antiviral, antitumor, antibacterial, and antifungal activities. The p-cymene has also been reported to act as an analgesic, antinociceptive, immunomodulatory, vasorelaxant and neuroprotective agent. Its anticancer effects are related to some mechanisms such as the inhibition of apoptosis and cell cycle arrest. In this review, we critically highlighted the in vitro and in vivo pharmacological properties of the p-cymene molecule, providing insight into its mechanisms of action and potential applications in drug discovery. In light of this finding, in-depth in vivo studies are strongly required to validate the safety and beneficial effects of the p-cymene molecule in human healthcare and industrial applications as a potential source of drug discovery.

High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes

Hydroxypyr(id)ones are a pharmaceutically important class of compounds that have shown potential in diverse areas of drug discovery. We investigated the 3-hydroxy-4-pyridones 1a-1c and 3-hydroxy-4-thiopyridones 1d-1f as well as their Ru(η⁶-p-cymene)Cl complexes 2a-2f, and report here the molecular structures of 1b and 1d as determined by X-ray diffraction analysis. Detailed cell biological investigations revealed potent cytotoxic activity, in particular of the 3-hydroxy-4-thiopyridones 1d-1f, while the Ru complexes of both compound types were less potent, despite still showing antiproliferative activity in the low μM range. The compounds did not modulate the cell cycle distribution of cancer cells but were cytostatic in A549 and cytotoxic in NCI-H522 non-small lung cancer cells, among other effects on cancer cells.

Ru(ii) water oxidation catalysts with 2,3-bis(2-pyridyl)pyrazine and tris(pyrazolyl)methane ligands: assembly of photo-active and catalytically active subunits in a dinuclear structure

Two mononuclear Ru(ii) complexes, i.e. [RuCl(κ³N-terpy)(κ²N-dpp)]PF₆ ([1]PF₆; terpy = 2,2':6',2''-terpyridine; dpp = 2,3-bis(2'-pyridyl-pyrazine) and [RuCl(κ³N-tpm)(κ²N-dpp)]Cl ([2]Cl; tpm = tris(1-pyrazolyl)methane), and one dinuclear complex, i.e. [Ru₂Cl(κ³N-tpm)(μ-κ²N:κ²N-dpp)Ru(κ²N-bpy)₂][PF₆]₃ ([3][PF₆]₃; bpy = 2,2'-bipyridine), have been synthesized and their water oxidation catalytic properties have been investigated. A combined DFT and experimental (³⁵Cl NMR and conductivity measurements) study aimed to elucidate the nature of [1]⁺ and [2]⁺ in aqueous solution has also been performed, indicating that one water molecule is allowed to enter the first coordination sphere of [2]⁺ in the ground state, replacing one tpm nitrogen. Conversely, in the case of [1]⁺, water coordination, assumed to be needed for the water oxidation process, presumably occurs following the oxidation of the metal. For all complexes, a catalytic wave has been detected in acetonitrile/water 1 : 1 (v/v) solution in the range 1.4-1.7 V vs. SCE. In all cases, water oxidation (investigated at pH < 8) takes place initially via a proton-coupled two-electron, two-proton process with the formation of an Ru(iv)[double bond, length as m-dash]O moiety, followed by one electron oxidation and water nucleophilic attack. The TON and TOF values (within the range of 16-33 and 1.3-2.2 h^-1, respectively) of the complexes are higher than those of the benchmark [Ru(LLL)(LL)(OH₂)]²⁺-type species (LLL and LL are tridentate and bidentate polypyridine ligands, respectively), which is [Ru(terpy)(bpm)(OH₂)]²⁺.

Organoruthenium(ii) nucleoside conjugates as colon cytotoxic agents

Eleven organoruthenium(ii) nucleoside conjugates are reported, showing high cytotoxicity in HCT116 colon cancer cells and independent uptake of nucleoside transporters.

Synthesis, characterization, DNA binding, topoisomerase I inhibition and antiproliferation activities of three new functionalized terpyridine platinum(II) complexes

Three new platinum(II) complexes with pendent morpholine were synthesized, namely complex 1 ([Pt(L)Cl]CF₃SO₃), complex 2 ([Pt(L)(NH₃)](CF₃SO₃)₂) and complex 3 ([Pt(L)(PPh₃)](CF₃SO₃)₂), where L = 4'-[4-(4-morpholinobutyloxy)phenyl]-2,2':6',2″-terpyridine and PPh₃ = triphenylphosphine. The detailed molecular structures of complex 3, L and its precursor L' (1,4'-[4-(4-bromobutyloxy)phenyl]-2,2':6',2″-terpyridine) were determined by single crystal X-ray diffraction. An evaluation of in vitro cytotoxicity for both ligand and complexes was performed by methyl thiazolyl tetrazolium (MTT) assay in three cancer cell lines and normal cells as the control, respectively. IC₅₀ values of complexes 1-3 were lower than those exhibited for the reference drug cisplatin, and selectivity of these complexes were greater than cisplatin. Among them, complex 3 with a leaving group PPh₃ was found to be the most efficacious complex against certain cell lines, especially for cisplatin-resistant A549cisR cells. These complexes were found to bind DNA, induce efficient DNA unwinding. Meanwhile, topoisomerase (Topo) I inhibitory activities by three complexes were detected, and a minimum inhibitory concentration of 15 μM of complex 3 was found totally inhibit Topo I activity.

Benzothiazole-Based Cycloplatinated Chromophores: Synthetic, Optical, and Biological Studies

Cycloplatinated complexes based on 2-(4-substituted)benzothiazole ligands of type [Pt(R-PBT-κC,N)Cl(L)] (PBT=2-phenylbenzothiazole; R=Br (1), Me₂ N (2); L=dimethyl sulfoxide (DMSO; a), 1,3,5- triaza-7-phosphaadamantane (PTA; b), triphenylphosphine 3,3',3''-trisulfonate (TPPTS; c)) and [Pt(Br-PBT-κC)Cl(PTA)₂ ] (3) are presented. On the basis of the photophysical data and time-dependent (TD)-DFT calculations (1 a and 2 a), the low-lying transitions (absorption and emission) were associated with ligand-center (LC) charge transfer, with minor metal-to-ligand charge transfer (MLCT), and intraligand charge transfer (ILCT) [Me₂ N-PBT→PBT] excited states, respectively. Simultaneous fluorescence/phosphorescence bands were found in fluid solutions (and also in the solid state for 2 a), which become dominated by triplet emission bands in rigid media at 77 K. The effect of the concentration on emissive behavior of 2 a, b indicated the occurrence of aggregation-induced luminescence properties related to the occurrence of metal-metal and π⋅⋅⋅π interactions, which are more enhanced in 2 a because of the less bulky DMSO ligand. The behavior of 2 a toward para-toluenesulfonic acid (PTSA) in aerated acetonitrile and to hydrogen chloride gas in the solid state has been evaluated, thus showing a clear reversible change between the ¹ ILCT and ³ LC/³ MLCT states due to protonation of the NMe₂ group (theoretical calculations on 2 a-H⁺ ). Solid 2 a undergoes a surprising oxidation of the Pt^II center to Pt^IV with concomitant deoxygenation of DMSO, under prolonged reaction with hydrogen chloride gas to afford the Pt^IV /dimethyl sulfide complex (mer-[Pt(Me₂ N-PBT-κC,N)Cl₃ (SMe₂ )]; mer-4), which evolves in solution to fac-4, as confirmed by X-ray studies. Cytotoxic activity studies on A549 and HeLa cell lines indicated cytotoxic activity of 1 b and 2 a, b. In addition, fluorescent cell microscopy revealed cytoplasmic staining, more visible in perinuclear areas. Inhibition of tubulin polymerization by 1 b in both cells is presented as a preliminary mechanism of its cytotoxic action.

A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand

Esterification of (4-hydroxyphenyl)diphenylphosphine, coordinated to the [Ru(η⁶-p-cymene)Cl₂] fragment, allows a series of bioactive carboxylic acids to be introduced directly into the organometallic molecule. Evaluation of the compounds on human ovarian cancer cells reveals synergistic enhancements in their antiproliferative activity relative to their bioactive organic and organometallic precursors.

Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand

The cytotoxic activities of novel Ru(ii) arene complexes with variably mono-substituted phosphine ligands have been assessed towards MDA-MB-231 and A2780 cancer cell lines.

Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution

The anticancer behaviour of Ru arene complexes can be tuned by an appropriate choice of the site and linkage of the bioactive group to the phosphane ligand.